Latest Drugs, Latest Approval in Antihyperuricemic agents

What are Antihyperuricemic agents?

Antihyperuricemic agents are also called antigout agents. These agents work to either correct overproduction or underexcretion of uric acid.

For the long term control of gout, hyperuricemia caused by formation of uric acid from purines, can be effectively controlled with these agents. The choice of xanthine oxidase inhibitors or uricosuric medicines is based on the level of urinary uric acid excretion, renal function, age of the patient, history of renal calculi and presence of tophi.

Name Updated
Pegloticase (Pegloticase [ peg-loe-ti-kase ]) 14-Aug-2023
Rasburicase (Rasburicase [ ras-bur-ih-kase ]) 12-Aug-2023
Elitek (Rasburicase [ ras-bur-ih-kase ]) 13-Jul-2023
Duzallo (Allopurinol and lesinurad [ al-oh-pure-i-nol-and-le-sin-ure-ad ]) 13-Jul-2023
Uloric (Febuxostat [ fe-bux-oh-stat ]) 12-Jul-2023
Krystexxa injection (Pegloticase [ peg-loe-ti-kase ]) 11-Jul-2023
Febuxostat (Febuxostat [ fe-bux-oh-stat ]) 10-Jul-2023
Allopurinol (Allopurinol (oral/injection) [ al-oh-pure-i-nol ]) 10-Jul-2023